Friday, 06 Dec 2019

You are here

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents. 

Risankizumab (Skyrizi), an interleukin-23 (IL-23) inhibitor, was FDA approved for use in psoriasis in April 2019, becoming the the third IL-23 inhibitor (includes guselkumab [Tremfya] and tildrakizumab [Ilumya]) approved in the last year for plaque psoriasis.

The IMMvent trial was a phase 3, randomised, double-blind, active-comparator-controlled trial that enrolled 605 adults with moderate-to-severe chronic plaque psoriasis and randomized them to either risankizumab (RIS) (150 mg subcutaneously at weeks 0 and 4 ) or adalimumab (ADA) (80 mg subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter during the first 16-weeks of the trial (part A). For weeks 16–44 (part B), adalimumab intermediate responders were re-randomised 1:1 to continue 40 mg adalimumab or switch to 150 mg risankizumab.

Co-primary endpoints in part A were a 90% improvement from baseline (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 16.

Nearly all of the RIS (98%) and ADA (96%)patients completed part A (first 16 weeks) of the study. 

At week 16, PASI 90 results were:

  • RIS - 72%
  • ADA - 47% (p<0·0001)

In part B, at week 44, the ADA intermediate responders, achieved a PASI 90 in 66% of RIS treated patients and 21% in those continuing ADA therapy (p<0·0001).

Risankizumab showed significantly greater efficacy than adalimumab in providing skin clearance in moderate-to-severe plaque psoriasis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week. 

Spondyloarthritis Affects Pregnancy Outcomes

A Danish registy has shown that the the prevalence of Spondyloarthritis (SpA) diagnosed prior to delivery has increased 5 fold in the last two decades and that SpA is associated with an increased risk of adverse pregnancy outcomes (APO).

IL-17 Inhibitors In Non-Radiographic Axial SpA

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Psoriatic Arthritis at ACR 2019

Below are several of the highlight studies in psoriatic arthritis (PsA) presented at the ACR 2019 annual meeting in Atlanta. 

New Treatments in Axial SpA from #ACR2019

There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS. The third area is the use of dual anti-IL17A and 17F drug bimekizumab in radiographic.